肾素-血管紧张素-醛固酮系统抑制剂多靶点干预治疗高血压的研究进展  

Research progress on multi-targeted interventions of renin-angiotensin-aldosterone system inhibitors for treatment of hypertension

作　　者：秦梦云 杨威[1] 吕媛媛 张明高 韩红彦[1] QIN Meng-yun;YANG Wei;LÜ Yuan-yuan;ZHANG Ming-gao;HAN Hong-yan(Department of Cardiovascular Medicine,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Wuhan 430060,China)

机构地区：[1]武汉科技大学附属天佑医院心内科,湖北武汉430060

出　　处：《现代药物与临床》2022年第2期439-444,共6页Drugs & Clinic

摘　　要：肾素-血管紧张素-醛固酮系统(RAAS)是参与高血压发病和维持不可或缺的环节;RAAS抑制剂治疗高血压被临床广泛应用,其中主要包括直接肾素抑制剂、血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂。它们作用于RAAS不同靶点,对RAAS抑制剂有效性的影响及其临床应用地位和意义一直被人们所关注,因此对三者各靶点作用特点的进行总结,以揭示RAAS抑制剂多靶点干预的重要性和意义。Renin-angiotensin-aldosterone system(RAAS) is an indispensable link in the pathogenesis and maintenance of hypertension. RAAS inhibitors, mainly including direct renin inhibitors, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are widely used in the treatment of hypertension. They act on different targets of RAAS, and their impact on the effectiveness of RAAS inhibition and their clinical application status and significance have been of interest. This article summarizes the characteristics of the three targets, to reveal the importance and significance of the intervention of different RAAS targets.

关 键 词：肾素-血管紧张素-醛固酮系统 直接肾素抑制剂 血管紧张素转换酶抑制剂 血管紧张素受体拮抗剂 高血压 研究进展 

分 类 号：R977[医药卫生—药品]